NewsBenzingaPerspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors Perspective Therapeutics Receives FDA Fast Track Designation For Development Of PSV359 For Adult Patients With Locally Advanced Unresectable And/Or Metastatic Fibroblast Activation Protein-Positive Solitary Fibrous Tumors Benzinga 2026.10.08 10:17 (GMT+0) Open on Benzinga Other news Mizuho Maintains Neutral on PBF Energy, Raises Price Target to $89 Crescent Energy Company Commences $1B Class A Common Stock Offering Mizuho Maintains Neutral on Marathon Petroleum, Raises Price Target to $457 Mizuho Maintains Neutral on HF Sinclair, Raises Price Target to $119 ReposiTrak And SPAR Canada Launch In-Store Merchandizing Program Touchless Retail Meta's New AI Assistant Will Know Who's Your Crush Before You Do
